Cannabidiol: Potential Treatment for Menstrual-Related Symptoms

Abstract

Review: Exploring Cannabidiol's Therapeutic Potential for Menstrual-Related Symptoms

This review examines the pioneering study, "Examination of the Effects of Cannabidiol on Menstrual-Related Symptoms," by Morgan L. Ferretti from the Department of Psychological Sciences at the University of Arkansas. The research is a collaborative effort with contributions from Taylor B. Stanley of Auburn University, Erica N. Peters of Canopy Growth Corporation, Marcel O. Bonn-Miller of Charlotte’s Web, and Jessica G. Irons of James Madison University merge expertise from academic and industrial sectors to investigate the effects of cannabidiol (CBD) on menstrual-related symptoms (MRS).

Published in "Experimental and Clinical Psychopharmacology," this study fills a significant gap in the existing literature by assessing the potential of CBD to mitigate the often debilitating symptoms associated with menstruation. This topic has not been extensively explored until now.

The research adopts a methodologically rigorous pre-post, randomized, open-label trial design to evaluate the impacts of oral CBD isolate on MRS. With participants assigned to two distinct dosing groups and followed over a period extending beyond the initial baseline assessment through three months of CBD consumption, the study meticulously documents the changes in MRS and related psychological outcomes.

Preliminary findings indicate significant reductions in MRS, alongside notable decreases in related symptoms such as irritability, anxiety, stress, and subjective severity of symptoms, without significant alterations in depression scores.

These results suggest CBD's potential efficacy in managing MRS, offering new insights into cannabinoid-based therapeutic strategies. The study's innovative approach and its implications for future research underscore the necessity for further investigations into CBD's role in treating MRS, including potential optimizations through combined formulations and varied administration methods.

This review acknowledges the study's contribution to the field and calls for continued exploration into the therapeutic possibilities of cannabinoids for menstrual-related discomfort.

Introduction

MRS encompasses a range of physiological and psychological symptoms experienced by about 75% of menstruating individuals, with 5%–8% suffering from moderate to severe manifestations. The cyclical nature of MRS means these symptoms can fluctuate in intensity throughout the menstrual cycle, complicating treatment approaches and impacting quality of life.

Traditional treatments have focused on managing physical symptoms, often overlooking the psychological dimensions of MRS, which can be just as debilitating. Given the limitations and side effects associated with existing interventions, there is a pressing need for alternative solutions. Cannabidiol (CBD), known for its therapeutic potential across various conditions, is a promising candidate due to its mood-regulating, anti-inflammatory, and analgesic properties.

Menstrual-related symptoms (MRS) present a considerable challenge for a significant portion of menstruating individuals, affecting their daily lives, mental health, and overall well-being. Despite the commonality of these symptoms, effective and comprehensive treatment options remain limited. The study under review marks an important step toward exploring cannabidiol (CBD) as a potential remedy for MRS, a subject that, until now, has been largely unexplored within the scientific community.

Accurate, up-to-date global statistics on the number of women experiencing menstrual-related symptoms (MRS) can vary due to differing study methodologies, definitions of MRS, and reporting practices across countries. However, research has widely acknowledged that a significant portion of menstruating individuals experience MRS at some point in their lives.

Study Overview

The study in question is a pioneering pre-post, randomized, open-label trial aimed at assessing the efficacy of oral CBD isolate in alleviating MRS. Participants were divided into two dosing groups (160 mg and 320 mg, taken twice daily) and monitored over a baseline period followed by three months of CBD consumption.

The study meticulously recorded changes in MRS and related outcomes, providing initial evidence of CBD's beneficial effects on MRS, including reductions in irritability, anxiety, stress, and the subjective severity of symptoms.

The critical outcomes measured were changes in MRS, irritability, anxiety, global impression of change, stress, and subjective severity of symptoms, with notable reductions observed in all areas except for depression scores. This research offers initial evidence suggesting the efficacy of CBD in managing MRS, marking an important step towards developing more effective treatments for these symptoms.

Results and Discussion

The findings reveal significant reductions in MRS across both dosing groups, with improvements noted from the first month of consumption and sustained over the study's duration. This outcome aligns with CBD's known therapeutic effects, offering a new avenue for MRS management.

Notably, the study observed no significant changes in depression scores, indicating that while CBD may alleviate specific psychological symptoms associated with MRS, its impact on depression remains unclear.

Current Treatment Options Are Limited

For menstrual-related symptoms (MRS), a variety of medications may be prescribed depending on the severity and type of symptoms experienced. The primary goal of these treatments is to alleviate discomfort and manage symptoms. Here's an overview of the types of drugs commonly prescribed for MRS:

Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs, such as ibuprofen (Advil, Motrin) and naproxen (Aleve), are often the first line of treatment for managing menstrual pain (dysmenorrhea) and inflammation. They work by inhibiting enzymes that contribute to inflammation and pain.

Oral Contraceptives (Birth Control Pills): Hormonal contraceptives can regulate or even eliminate periods, thereby reducing or preventing the occurrence of menstrual cramps and other symptoms. They work by controlling hormone levels that influence the menstrual cycle.

Antidepressants: For individuals experiencing severe premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD), which include psychological symptoms such as depression and anxiety, selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (Prozac) and sertraline (Zoloft) may be prescribed.

Diuretics: Also known as "water pills," diuretics like spironolactone (Aldactone) can help relieve bloating and breast tenderness by encouraging the body to eliminate excess fluid through urine.

Gonadotropin-releasing hormone (GnRH) agonists: These drugs, such as leuprolide (Lupron), can induce a temporary menopause-like state by reducing the body's production of estrogen and progesterone, which can help alleviate severe menstrual symptoms. However, they are typically used as a last resort due to significant side effects and are often prescribed with add-back therapy to minimize bone density loss.

Antianxiety medications: For those whose MRS include severe anxiety symptoms, antianxiety medications may be considered, although this is less common and typically only in specific circumstances.

Over-the-counter (OTC) pain relievers: Besides NSAIDs, other OTC pain relievers, such as acetaminophen (Tylenol), may provide relief from menstrual cramps and pain, although they do not reduce inflammation.

Public Health Significance

This study's implications extend beyond its immediate findings. As the first investigation, it opens the door for further research into CBD's potential to address a gap in MRS treatment options. CBD's safety profile, coupled with its broad therapeutic range, positions it as an attractive alternative to current treatments, which often carry undesirable side effects.

The public health significance of menstrual-related symptoms (MRS) extends far beyond individual health concerns, affecting broader societal, economic, and healthcare systems. Understanding and addressing MRS is crucial for promoting gender equity, improving population health, and reducing healthcare costs. Below are key aspects that highlight the public health significance of MRS:

Widespread Prevalence

MRS affects a significant proportion of the global female population of reproductive age, making it a common public health issue. The near-universal nature of menstruation means that the impacts of MRS are experienced across cultures, economic statuses, and age groups.

Economic Impact

The economic burden of MRS includes direct medical costs for treatments and indirect costs such as lost productivity and absenteeism from work or school. Severe symptoms can lead to frequent healthcare visits, increased medication use, and even hospitalizations, contributing to higher healthcare expenditures.

Educational Impact

Adolescents and young adults experiencing MRS may have decreased school attendance and performance, impacting their educational outcomes. This can have long-term effects on their career opportunities and economic independence.

Mental Health Concerns

The psychological symptoms associated with MRS, including those from PMS and PMDD, contribute to the overall mental health burden. Addressing these symptoms is critical for mental health promotion and preventing long-term psychiatric conditions.

Quality of Life

MRS can severely impact the quality of life, affecting physical well-being, emotional health, and social functioning. Public health initiatives that acknowledge and address these symptoms can improve life satisfaction and well-being for a significant portion of the population.

Gender Equity in Health Care

Historically, women's health issues, including MRS, have been under-researched and marginalized in healthcare systems. Recognizing the importance of MRS in public health is a step toward gender equity in health research, policy, and practice.

Health Literacy and Awareness

Increased awareness and education about MRS can lead to better self-management, earlier diagnosis of related conditions (e.g., endometriosis, PCOS), and reduced stigma around menstruation. Public health campaigns can be vital in improving health literacy concerning MRS.

Policy and Workplace Changes

Recognizing the impact of MRS can lead to policy changes, including workplace accommodations (e.g., menstrual leave policies) and school health programs, supporting individuals affected by these symptoms.

Limitations and Future Research

While promising, the study's limitations underscore the need for further research. The absence of a placebo group is evident, so this can't be entirely ruled out as contributing to the observed improvements.

The study's open-label design and reliance on self-reported data also introduce potential biases. Future studies should incorporate placebo controls, diverse participant samples, and objective compliance verification to build on these initial findings.

Research into the effects of cannabidiol (CBD) on menstrual-related symptoms (MRS) is a quickly emerging field, promising potential relief for many individuals. However, several limitations exist in the current body of research, which must be addressed to fully understand and harness CBD's therapeutic potential for MRS:

Limited Clinical Trials

Most studies on CBD and MRS are in the early stages, often involving small sample sizes and needing long-term data. This makes it challenging to generalize findings across the broader population or understand CBD's long-term safety and efficacy for managing MRS.

Lack of Standardization

There is significant variability in the CBD products used across studies, including differences in dosage, formulation (isolate vs. full-spectrum), and administration methods. This variability complicates the comparison of results across studies and the development of standardized treatment protocols.

Placebo Effects

Many studies on CBD and MRS do not include a placebo-controlled group, making it difficult to determine whether observed effects are due to CBD's pharmacological action or result from placebo effects. Placebo-controlled trials are crucial to validate the efficacy of CBD.

Diverse Symptoms

MRS encompasses a wide range of physical and psychological symptoms. Research often focuses on a limited subset of these symptoms, overlooking individuals' complex and varied experiences with MRS. Comprehensive studies that consider the full spectrum of MRS are needed.

Regulatory and Legal Challenges

The legal status of CBD varies by region, impacting the ability to conduct research and limiting access to standardized, high-quality CBD products for study purposes. These regulatory hurdles can stifle research efforts and innovation in this area.

Subjective Reporting

Many studies rely on self-reported measures of symptom relief, which can be subjective and influenced by individual perceptions and expectations. Objective measures, alongside subjective reports, could provide a more accurate assessment of CBD's effects on MRS.

Underrepresentation of Populations

Research often needs to adequately represent the diversity of the population affected by MRS, including individuals of various ages, races, ethnicities, and health conditions. A more inclusive approach is needed to ensure that findings apply to all who experience MRS.

Interaction with Existing Treatments

There is limited understanding of how CBD interacts with other medications or treatments for MRS. Research exploring these interactions is necessary to ensure the safe and effective use of CBD alongside other therapies.

Addressing these limitations requires a concerted effort from researchers, healthcare providers, and policymakers. Expanding the scope of research, standardizing study methodologies, and fostering a regulatory environment conducive to CBD research are critical to gain very accurate data.

Conclusion

In conclusion, the study presents compelling evidence of CBD's potential to manage MRS, highlighting reductions in a wide range of symptoms. Its significance lies in its immediate findings and its contribution to a growing body of research exploring cannabis-derived compounds for health and wellness. As interest in alternative and holistic treatment options continues to grow, studies like this pave the way for innovative approaches to managing menstrual-related symptoms, offering hope to those for whom conventional treatments have fallen short. Further research is essential to understand CBD's role in MRS management fully and to optimize its use for this purpose, potentially transforming the way MRS gets treated in future medicinal applications.

-Mike Robinson, Founder, Global Cannabinoid Research Center

References:

Morgan L. Ferretti , Taylor B. Stanley, Erica N. Peters, Marcel O. Bonn-Miller, March 2024, Examination of the Effects of Cannabidiol on Menstrual-Related Symptoms Online First Posting

Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017). Inverted U-shaped dose–response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology, 8, Article Article 259. https://doi.org/10.3389/fphar.2017.00259

Curtiss JE, Levine DS, Ander I, Baker AW. Cognitive-Behavioral Treatments for Anxiety and Stress-Related Disorders. Focus (Am Psychiatr Publ). 2021 Jun;19(2):184-189. doi: 10.1176/appi.focus.20200045. Epub 2021 Jun 17. PMID: 34690581; PMCID: PMC8475916

Kaspi, S. P., Otto, M. W., Pollack, M. H., Eppinger, S., & Rosenbaum, J. F. (1994). Premenstrual exacerbation of symptoms in women with panic disorder. Journal of Anxiety Disorders, 8(2), 131–138. https://doi.org/10.1016/0887-6185(94)90011-6

Rapin L, Gamaoun R, El Hage C, Arboleda MF, Prosk E. Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic. J Cannabis Res. 2021 Jun 23;3(1):19. doi: 10.1186/s42238-021-00078-w. PMID: 34162446; PMCID: PMC8223341

Sholler DJ, Schoene L, Spindle TR. Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Curr Addict Rep. 2020 Sep;7(3):405-412. doi: 10.1007/s40429-020-00326-8. Epub 2020 Jul 25. PMID: 33585159; PMCID: PMC7880228

Siddall, P.J., MacLeod, R.D. (2019). Physical, Psychological/Psychiatric, Social, and Spiritual Problems and Symptoms. In: MacLeod, R., Van den Block, L. (eds) Textbook of Palliative Care. Springer, Cham. https://doi.org/10.1007/978-3-319-77740-5_9

Larsen, C., & Shahinas, J. (2020). Dosage, efficacy and safety of cannabidiol administration in adults: A systematic review of human trials. Journal of Clinical Medicine Research, 12(3), 129–141. https://doi.org/10.14740/jocmr4090